CD226 and myeloid leukemia: As a first step, we used flow cytometry to determine DNAM-1 surface expression on cancer cell lines representing a wide range of myeloid malignancies: K562 (chronic myeloid leukemia), U937 (pro-myelocytic leukemia), KG-1 (AML M6), EOL-1 (AML M4), Kasumi-1 (AML M2), HL-60 (AML M2), TF-1 (AML M6) (Fig. 1A).